Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson : Oklahoma judge approves Teva's $85 million opioid settlement

share with twitter share with LinkedIn share with facebook
share via e-mail
06/24/2019 | 06:29pm EDT
FILE PHOTO: The logo of Teva Pharmaceutical Industries is seen during a news conference in Tel Aviv

(Reuters) - An Oklahoma judge on Monday approved a revised $85 million (£66.7 million) settlement with Teva Pharmaceutical Industries Ltd resolving claims by the state's attorney general that the drugmaker helped fuel the U.S. opioid epidemic.

The decision by Cleveland County District Judge Thad Balkman in Norman, Oklahoma came after the state's attorney general, governor and top lawmakers resolved a dispute over how the money should be deposited and spent.

Oklahoma Attorney General Mike Hunter struck an initial settlement with Teva on May 26, just days before the Israel-based drugmaker was set to face trial alongside Johnson & Johnson, which is continuing to fight the case.

The settlement resolved claims that Teva and other drugmakers helped cause the epidemic by marketing opioids as safe and effective for everyday pain while downplaying their addictive qualities.

The case is one of around 2,000 by state and local governments seeking to hold drugmakers responsible for an epidemic the U.S. Centers for Disease Control and Prevention says led to a record 47,600 opioid-related overdose deaths in 2017.

Teva's deal came just days before the Israel-based drugmaker was set to face trial in the case, and two days after Oklahoma Governor Kevin Stitt signed a bill into law that required funds recovered in lawsuits by the state to be deposited into the state's treasury.

The law followed criticism by state legislators that money from an earlier, $270 million settlement in the case with Purdue Pharma LP in March was not deposited in the state's coffers for lawmakers to determine its use.

Instead, nearly $200 million of that March settlement went towards creating an addiction treatment and research centre at Oklahoma State University.

Under Teva's initial settlement, the $85 million was to be deposited into a court-controlled account pending the outcome of J&J's trial.

Hunter's office argued Teva's settlement should be combined with any money J&J must pay to help remedy, or abate, what the state says is a public nuisance that will cost $17.5 billion to remedy over 30 years. J&J denies the allegations.

But Stitt and Republican leaders of the state's legislature argued any funds should be deposited directly with the state's treasury.

Under the revised accord, money from Teva's settlement would be deposited in a fund with the state and only be used to address the opioid epidemic, subjected to future legislation, according to court papers. Teva did not admit wrongdoing.

(Reporting by Nate Raymond in New York; Editing by Bill Berkrot and Susan Thomas)

By Nate Raymond

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 0.68% 132.25 Delayed Quote.2.48%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
08/19JOHNSON & JOHNSON : Congo to use second vaccine to fight Ebola
08/16JOHNSON & JOHNSON INVESTIGATION UPDA : Kahn Swick & Foti, LLC Continues to Inves..
08/16JOHNSON & JOHNSON : Ebola Crisis-The Vaccines Debate
08/15JOHNSON & JOHNSON : Janssen Announces European Commission Approval of Imbruvica ..
08/13JOHNSON & JOHNSON : J&J's Janssen Gets EC OK for Expanded Use of Imbruvica
08/12JOHNSON & JOHNSON : Thinking about trading options or stock in AbbVie, Bristol-M..
08/12JOHNSON & JOHNSON : Janssen Announces U.S. FDA Accelerated Approval for SIRTURO ..
08/09JOHNSON & JOHNSON : Janssen Announces U.S. FDA Accelerated Approval for SIRTUROÒ..
08/09Canada enacts drug price crackdown, in blow to pharmaceutical industry
08/09WHAT IS THE KEY OUTCOMES ANALYSIS OF : Pfizer, Amgen, Novartis, Bayer, Johnson &..
More news
Financials (USD)
Sales 2019 81 594 M
EBIT 2019 25 389 M
Net income 2019 18 319 M
Debt 2019 6 116 M
Yield 2019 2,84%
P/E ratio 2019 19,7x
P/E ratio 2020 17,4x
EV / Sales2019 4,35x
EV / Sales2020 4,08x
Capitalization 349 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 148,50  $
Last Close Price 132,25  $
Spread / Highest target 27,8%
Spread / Average Target 12,3%
Spread / Lowest Target -6,24%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.48%346 681
ROCHE HOLDING LTD.12.24%238 299
MERCK AND COMPANY12.80%217 785
NOVARTIS17.81%204 677
PFIZER-19.40%191 651
NOVO NORDISK AS16.65%122 509